{"DataElement":{"publicId":"6029625","version":"1","preferredName":"Stage Prognostic Factor Pathologic Neoplasm Size Code","preferredDefinition":"Variable that records the size of a solid primary tumor that has been resected.","longName":"6027942v1.0:6024180v1.0","context":"PS-CC","contextVersion":"1","DataElementConcept":{"publicId":"6027942","version":"1","preferredName":"Stage Prognostic Factor Pathologic Neoplasm Size","preferredDefinition":"The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body._The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome._Caused by or altered by or manifesting disease or pathology._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The physical magnitude of something.","longName":"2688190v1.0:6027940v1.0","context":"PS-CC","contextVersion":"1","ObjectClass":{"publicId":"2688190","version":"1","preferredName":"Stage Prognostic Factor","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.:The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","longName":"C16899:C18959","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prognostic Factor","conceptCode":"C18959","definition":"The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C0FC8A1-D62E-5124-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-09","modifiedBy":"ONEDATA","dateModified":"2007-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6027940","version":"1","preferredName":"Pathologic Neoplasm Size","preferredDefinition":"Caused by or altered by or manifesting disease or pathology.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:The physical magnitude of something.","longName":"C25610:C3262:C25681","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Size","conceptCode":"C25681","definition":"The physical magnitude of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D96DDE7-5261-2930-E053-F662850AE5F8","latestVersionIndicator":"Yes","beginDate":"2017-11-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-09","modifiedBy":"ONEDATA","dateModified":"2017-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008548","version":"1","preferredName":"Tumor Measurements","preferredDefinition":"any measurements, including linear dimensions, volume, and weight, of a patient's tumor.","longName":"TUMOR_MSRMTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B228CD1A-3A0C-4C11-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D96DDE7-5272-2930-E053-F662850AE5F8","latestVersionIndicator":"Yes","beginDate":"2017-11-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-09","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.09.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6024180","version":"1","preferredName":"Collaborative Staging Independence Neoplasm Size Code","preferredDefinition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits)._Freedom from control or influence of another or others factors._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The physical magnitude of something._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6024180v1.0","context":"PS-CC","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008548","version":"1","preferredName":"Tumor Measurements","preferredDefinition":"any measurements, including linear dimensions, volume, and weight, of a patient's tumor.","longName":"TUMOR_MSRMTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B228CD1A-3A0C-4C11-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6024179","version":"1","preferredName":"Collaborative Staging Independence Neoplasm Size Code","preferredDefinition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).:Freedom from control or influence of another or others factors.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:The physical magnitude of something.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6024179v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collaborative Staging","conceptCode":"C62575","definition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Independence","conceptCode":"C61366","definition":"Freedom from control or influence of another or others factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Size","conceptCode":"C25681","definition":"The physical magnitude of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D1C48F8-8E70-619F-E053-F662850A335D","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-03","modifiedBy":"ONEDATA","dateModified":"2017-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D1C48F8-8E81-619F-E053-F662850A335D","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-03","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.03.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2193114","version":"1","longName":"Division of Cancer Control and Population Sciences","context":"PS-CC","ClassificationSchemeItems":[{"publicId":"5899845","version":"1","longName":"StageProgFactors16","context":"PS-CC"},{"publicId":"5899833","version":"1","longName":"NAACCR 16","context":"PS-CC"},{"publicId":"7464319","version":"1","longName":"StageProgFactors18","context":"PS-CC"},{"publicId":"7464305","version":"1","longName":"NAACCR 18","context":"PS-CC"}]}],"AlternateNames":[{"name":"754","type":"NAACCR Item #","context":"PS-CC"},{"name":"Tumor Size Pathologic","type":"NAACCR Item Name","context":"PS-CC"}],"ReferenceDocuments":[{"name":"NAACCR 16, Data Stds/Dict.","type":"REFERENCE","description":"For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)","url":"https://www.naaccr.org/data-standards-data-dictionary/","context":"PS-CC"},{"name":"Pathologic Tumor Size","type":"Preferred Question Text","description":"Pathologic Tumor Size","url":null,"context":"PS-CC"},{"name":"Valid Values","type":"VALID_VALUE_SOURCE","description":"See NAACCR 16, Data Stds/Dictionary, Data Dictionary section for a list of code sources and coding instructions.","url":"https://www.naaccr.org/data-standards-data-dictionary/","context":"PS-CC"}],"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E33E18C-358F-735B-E053-F662850A4112","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-17","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}